I believe Avii wants to locate it (the Act IV Rindo protocol that is supposed to be attached to the Lancet Journal article and is not) so he can further compare that trial's selection criteria to DCVax-L's. Primarily, he wants to see how the MRI's were used in that prior to actually enrolling patients in the Rindo trial. He knows how they were used for the DCVax-L trial - to prevent rapid and chemo/rad pseudo-progressors from entering the main arm of this trial.
But he wants the criteria for how they were used to for the Rindo trial. Did they exclude rapid progressors or allow them in? If they excluded them, and included psPD patients, than that would mean they removed those likely to die first and kept those likely to die last (apologies for putting that so crudely). If this were the case, and DCVax-L still had a better comparison, that would be more remarkable.
However, if they removed both rapid and psPD, than the comparison of patients as they began the trial would be more equal. I hope this makes sense. I believe that's what and why Avii wants the protocol.
Market Data 
Markets 
AI
